CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells |
| |
Authors: | Richard D. Lopez Edmund K. Waller Pei-Hua Lu Robert S. Negrin |
| |
Affiliation: | (1) Bone Marrow Transplantation Program, University of Alabama at Birmingham, 541 THT, 1900 University Boulevard, Birmingham, AL 35294, USA e-mail: richard.lopez@ccc.uab.edu Tel.: +1-205-9750323; Fax: +1-205-9758394, US;(2) Division of Bone Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA, US;(3) Division of Hematology-Oncology, Bone Marrow Transplant-Leukemia Program, Emory University School of Medicine, Atlanta, Georgia, USA, GE |
| |
Abstract: | A small proportion of human CD3+ T lymphocytes are known to co-express CD56, an antigen usually restricted in its expression to natural killer (NK) cells. Whereas the in vivo function of CD3+ CD56+ T cells remains unknown, we and others have previously shown that both in vitro and in vivo, these cells can mediate a significantly greater degree of MHC-unrestricted cytotoxicity against a variety of human tumor cells when compared to either CD3+ CD56− T cells or lymphokine activated killer (LAK) cells. While the mechanisms regulating the in vivo expansion of CD56+ T cells are not known, here we demonstrate the importance of CD2-mediated IL-12-dependent signals in the in vitro expansion of CD56+ T cells. Specifically, we show that activated monocytes provide a contact dependent factor (CD58/LFA-3) and a soluble factor (IL-12), both critical for the in vitro expansion of CD56+ T cells. The biological and therapeutic implications of these findings are discussed. Received: 4 May 2000 / Accepted: 25 August 2000 |
| |
Keywords: | Monocytes/macrophages T lymphocytes IL-12 CD56/NCAM immunotherapy |
本文献已被 PubMed SpringerLink 等数据库收录! |
|